Companion-animal dermatology and urinary tract infection control require cephalexin monohydrate to be processed into immediate-release cores in which the API addition ratio is set by compressibility and content uniformity rather than by labeled dose alone. For 150 mg, 300 mg, and 600 mg label strengths, cephalexin monohydrate typically occupies 35–50 wt% of the uncoated core mass; a 600 mg score-line tablet therefore carries a core mass of approximately 1,200–1,350 mg, while lower strengths are diluted with microcrystalline cellulose and lactose monohydrate to maintain bulk density between 0.55 g/cm³ and 0.65 g/cm³. Uniformity of dosage units is tested according to USP <905> with an acceptance value of ≤ 15.0 for 10 units, and dissolution is performed on USP <711> apparatus 2 at 50 rpm in 900 mL of water or pH 4.0 acetate buffer, with Q = 80% at 30 min. Downstream production consists of high-shear wet granulation in a 75 L vertical granulator using povidone K30 binder, wet-massing to an endpoint torque of 2.5–4.0 N·m, fluid-bed drying with inlet air at 55–65 °C and product temperature held at 40–45 °C, and dry milling through a 0.032 in rasping screen before lubrication with 0.5 wt% magnesium stearate in a bin blender. Rotary compression is run at 10–18 kN with tablet hardness of 8–14 kp and friability below 1.0%; capping above 18 kN is observed when granule moisture exceeds 6.0 wt%. Finished veterinary presentations include scored uncoated tablets, flavored chewable tablets, and hard gelatin capsules in 250 mg and 500 mg strengths for dose titration in dogs and cats; tablet splitting is not recommended for cats below 4 kg because split-mass variability can exceed 10% of the intended dose.

Why Does Reconstitution pH Govern Aqueous Oral Suspension Stability?

During reconstitution, dry cephalexin powder is hydrated into a buffered suspension because cephalexin monohydrate undergoes pH-dependent solubility and beta-lactam ring hydrolysis. The dry blend is formulated to deliver 125 mg/5 mL or 250 mg/5 mL after adding purified water to the bottle mark; cephalexin monohydrate loading in the dry powder is typically 10–20 wt%, and the suspending matrix consists of sucrose, xanthan gum, sodium benzoate, and sodium citrate dihydrate at 0.05–0.10 M buffer concentration. The reconstituted suspension is buffered to pH 4.2–5.0; formulation above pH 5.5 lowers viscosity and accelerates ring opening, so citrate buffering is optimized at the lower end of the accepted range. The suspending vehicle is adjusted to an apparent viscosity of 80–150 mPa·s at 20 s⁻¹ and 25 °C to balance sediment formation against syringeability. Microbial quality is controlled under USP <61> and USP <62>, preservative efficacy under USP <51>, and pH under Ph. Eur. 2.2.3; uniformity of the dry powder is judged by USP <905> after reconstitution. Manufacturing uses low-shear V-blending of the milled API and excipients at 25 rpm for 25–35 min, followed by gravimetric powder filling into HDPE bottles and induction sealing under ≤40% RH at 20–25 °C. After reconstitution, the suspension is labeled for 14 days at 2–8 °C; storage at 25 °C falls outside the validated stability boundary. Finished product types include multi-dose oral suspension bottles with graduated polypropylene syringes, unit-dose oral solution cups, and compounded oral pastes prepared under USP <795> where extralabel use is permitted.

Medicated drinking water formulations containing cephalexin monohydrate are built around pH-adjusted soluble powder platforms in which API loading must be matched to field water alkalinity and ambient temperature. A representative sachet formulation contains 20 wt% cephalexin monohydrate, anhydrous citric acid, sodium carbonate, lactose monohydrate, and colloidal silica; one 100 g sachet reconstituted into 200 L of drinking water yields 100 mg/L cephalexin, with the effervescent acid-carbonate system lowering local pH to 4.0–5.0 to solubilize the API and reduce beta-lactam hydrolysis. Powder production uses direct blending in a ribbon mixer at 20 rpm for 30 min, followed by nitrogen-flushed sachet filling and in-line checkweighing that rejects fills outside ±2.5% of target. Blend uniformity is verified by stratified sampling under the FDA guidance for powder blends, with an acceptance relative standard deviation of ≤5.0%; microbial limits are controlled under USP <61> and USP <62>, and loss on drying under USP <731> is held at ≤2.0% on release. Operational boundaries include water pH above 8.0, bicarbonate hardness above 300 mg/L CaCO₃, and water temperature above 25 °C, all of which reduce solubility and chemical stability; proportioner stock solutions are limited to 24 h at 2–8 °C. Finished product forms are foil-lined sachets for header tanks, bulk water-soluble powder pails for medicator proportioners, and pre-weighed powder pouches for individual pens in authorized poultry or swine applications.

When Cephalexin Sodium Is Freeze-Dried for Veterinary Parenteral Use

For sterile veterinary parenteral products, cephalexin sodium is processed as a lyophilized cake because the beta-lactam ring is degraded by moist-heat sterilization and by prolonged aqueous exposure. The formulation contains cephalexin sodium equivalent to 1 g or 4 g cephalexin per Type I glass vial meeting USP <660>, with mannitol bulking agent at 2–5 wt%, and is reconstituted with Water for Injection to 100 mg/mL or 250 mg/mL immediately before intramuscular or subcutaneous administration. Manufacturing includes dissolution at 5–15 °C, pH adjustment to 5.5–6.5, sterile filtration through a 0.22 µm PVDF membrane, and aseptic filling under ISO 5 conditions. Lyophilization maintains product temperature below 25 °C during primary drying and chamber pressure at 50–150 mTorr; cake collapse is prevented by keeping the annealing shelf temperature below -20 °C. Sterility is evaluated under USP <71>, bacterial endotoxins under USP <85>, and subvisible particulate matter under USP <788> with limits of ≤6,000 particles per vial for ≥10 µm and ≤600 particles per vial for ≥25 µm. Because published data for this specific veterinary configuration is limited, reconstituted solution stability is conservatively fixed at 24 h at 2–8 °C; admixture with aminoglycosides is contraindicated due to mutual inactivation. Finished presentations include lyophilized vials for reconstitution, pre-diluted injectable solutions in sterile single-dose vials, and freeze-dried powders co-packaged with diluent for field administration.

The release-control matrix across the application routes is consolidated below; limits are release specifications, not formulation targets.

Fluid-Bed Granulation Parameters for Unit-Dose Oral Granules

Cephalexin oral granules for direct administration to horses are produced by top-spray fluid-bed granulation to yield discrete, free-flowing granules with controlled particle-size distribution. The addition ratio is typically 10–20 wt% cephalexin monohydrate, with sucrose or maltodextrin as substrate, povidone K25 as binder, and citric acid to adjust the granule microenvironment to pH 4.5–5.5; a 2.5 g sachet at 20 wt% delivers 500 mg cephalexin, and a 5 g sachet delivers 1,000 mg for large-animal dose scaling. The process uses a top-spray fluid bed with inlet air temperature 55–65 °C, product bed temperature 38–42 °C, spray rate 15–25 g/min for a 10 kg batch, and atomization air pressure 1.5–2.0 bar; after drying to loss on drying ≤3.0%, granules are screened through 150–850 µm sieves, and fines below 150 µm are removed to reduce dust and dose variability. Particle-size distribution is measured under USP <786> or Ph. Eur. 2.9.38, and microbial quality follows USP <61> and USP <62>; stability is assigned under VICH GL3 conditions. Filling of unit-dose sachets is performed at ≤40% RH with a weight tolerance of ±3%, and desiccant-protected overwrap is applied when bulk containers exceed 250 g. Finished products include unit-dose sachets for oral administration or top-dressing in equine feed, bulk granules with calibrated scoops for hospital use, and granules incorporated into capsule shells for dose-limited companion animals.

Isolating the Premix from Conditioning Heat and Moisture

At standard pellet conditioning temperatures above 70 °C and moisture above 12%, unprotected cephalexin monohydrate undergoes accelerated beta-lactam ring opening; this thermal constraint shifts medicated feed production away from conventional mash pelleting toward post-pellet coating or meal premixing. In jurisdictions where cephalexin medicated feed is authorized, the premix is formulated at 5–10 wt% cephalexin monohydrate on a calcium carbonate or wheat middlings carrier, and final feed inclusion is calculated from mg/kg body weight and daily feed intake rather than from a fixed feed percentage. Production for pelleted feed applies the premix as a post-pellet liquid spray or vacuum coating onto cooled pellets at ≤35 °C, using a vegetable oil or hydrogenated fat carrier at 1–3 wt% of pellet mass to bind the premix to the pellet surface and limit segregation; meal products are produced in a ribbon mixer with blend uniformity acceptance of ≤5.0% relative standard deviation under FDA stratified sampling guidance. Compliance is maintained under 21 CFR 225 for medicated feed cGMP in the US, Regulation (EC) No 183/2005 for feed hygiene in the EU, and veterinary authorization under Regulation (EU) 2019/6. Conventional pelleting at 70–90 °C is excluded for unprotected cephalexin premix; heat-stable coated granules, if used, require dissolution verification in simulated gastric fluid under USP <711>. Storage is limited to ≤25 °C and ≤60% RH, and carryover flush sequences are defined to prevent cross-contamination in multi-species feed mills. Finished product types include post-pellet coated medicated feed, meal premix for on-farm mixing, and mineral carrier bags for authorized veterinary use.